Scarica l'app Stockscreener
0.37
3.97%
-0.0153
Dopo l'orario di chiusura:
.36
-0.01
-2.70%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché TNXP Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.3853
Aprire:
$0.3848
Volume 24 ore:
77.21M
Relative Volume:
0.85
Capitalizzazione di mercato:
$69.15M
Reddito:
-
Utile/perdita netta:
$-121.02M
Rapporto P/E:
-0.0198
EPS:
-18.6875
Flusso di cassa netto:
$-114.09M
1 W Prestazione:
-35.09%
1M Prestazione:
+95.97%
6M Prestazione:
-67.11%
1 anno Prestazione:
-97.18%
Intervallo 1D:
$0.35
$0.3919
Intervallo di 1 settimana:
$0.35
$0.6999
Portata 52W:
$0.118
$14.08
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Nome
Tonix Pharmaceuticals Holding Corp
Settore
Industria
Telefono
212-980-9155
Indirizzo
26 MAIN STREET, SUITE 101, CHATHAM, NY
Confronta TNXP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
0.37 | 69.15M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.65 | 105.75B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.68 | 78.76B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
632.04 | 37.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.50 | 31.28B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.77 | 27.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-04-18 | Iniziato | Noble Capital Markets | Outperform |
| 2019-04-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Downgrade | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Reiterato | Oppenheimer | Outperform |
| 2015-11-04 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-06-12 | Iniziato | Oppenheimer | Outperform |
| 2015-02-17 | Reiterato | ROTH Capital | Buy |
| 2014-09-29 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 2.6%Time to Sell? - MarketBeat
Certain Warrants of Tonix Pharmaceuticals Holding Corp. are subject to a Lock-Up Agreement Ending on 26-DEC-2024. - Marketscreener.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 4.4%Time to Sell? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 3.2%What's Next? - MarketBeat
FDA sets review goal date for Tonix fibromyalgia drug By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 26.8%Should You Sell? - MarketBeat
Tonix Pharma Awaits FDA Decision on TNX-102 SL - TipRanks
FDA sets review goal date for Tonix fibromyalgia drug - Investing.com
Tonix Pharmaceuticals Announces PDUFA Goal Date of August - GlobeNewswire
Tonix Pharmaceuticals' Groundbreaking Fibromyalgia Drug Gets FDA Fast Track & PDUFA Date - StockTitan
StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) - MarketBeat
Tonix Pharmaceuticals ups offering to $250 million - Investing.com India
Tonix Pharmaceuticals ups offering to $250 million By Investing.com - Investing.com Canada
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 11.3%Here's Why - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 3.7%Should You Sell? - MarketBeat
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket - Benzinga
Tonix Pharmaceuticals Holding Corp. Announces Fda Acceptance of the New Drug Application for Tnx-102 Sl for Fibromyalgia - Marketscreener.com
FDA accepts new fibromyalgia drug application from Tonix Pharma By Investing.com - Investing.com Australia
FDA Accepts NDA for Tonix’s Sleep-Improving Drug for Fibromyalgia - Sleep Review
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
TSX 60 Capped Index (TXCI) QuotePress Release - The Globe and Mail
Tonix Pharma’s TNX-102 SL Nears FDA Approval Milestone - TipRanks
Nasdaq 100 Index (IUXX) QuotePress Release - The Globe and Mail
What's Going On With Tonix Pharmaceuticals Stock Today? - Benzinga
FDA accepts Tonix’s NDA for non-opioid fibromyalgia drug TNX-102 SL - Invezz
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Tonix Pharmaceuticals Gets FDA Review of Fibromyalgia Drug - Marketscreener.com
Tonix stock jumps on FDA review for pain drug (TNXP:NASDAQ) - Seeking Alpha
FDA accepts new fibromyalgia drug application from Tonix Pharma - Investing.com
Tonix Pharmaceuticals Announces FDA Acceptance of the New - GlobeNewswire
Tonix's Breakthrough Fibromyalgia Drug Takes Major Step Forward with FDA NDA Acceptance - StockTitan
Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights - citybiz
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - Benzinga
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Quotes, Forecast and News Summary - Benzinga
Certain Options of Tonix Pharmaceuticals Holding Corp. are subject to a Lock-Up Agreement Ending on 11-DEC-2024. - Marketscreener.com
Certain Common Stock of Tonix Pharmaceuticals Holding Corp. are subject to a Lock-Up Agreement Ending on 11-DEC-2024. - Marketscreener.com
Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers - BioSpace
Tranche Update on Tonix Pharmaceuticals Holding Corp.'s Equity Buyback Plan announced on January 25, 2023. - Marketscreener.com
Tranche Update on Tonix Pharmaceuticals Holding Corp.'s Equity Buyback Plan announced on September 6, 2024. - Marketscreener.com
Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires - GlobeNewswire
TNXP: NDA Filed for TNX-102 SL in Fibromyalgia… - Yahoo Finance
Tonix Pharmaceuticals Holding (STU:TPM0) Operating Income : €-74.27 Mil (TTM As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (STU:TPM0) EBITDA per Share : €-24.48 (TTM As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) FCF Yield % : -195.15 (As of Dec. 01, 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) EV-to-Revenue : 1.46 (As of Dec. 01, 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (STU:TPM0) Capex-to-Revenue : 0.00 (As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (STU:TPM0) PS Ratio : 27.04 (As of Dec. 01, 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) Inventories, Inven - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) Long-Term Debt : €4.66 Mil (As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (FRA:TPM0) Retained Earnings : €-638.44 Mil (As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding Corp Azioni (TNXP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.50%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):